Sonrotoclax Meets Primary ORR End Point in Mantle Cell Lymphoma
Written by
Cancer Network
Published
0
comments
0
min
The safety profile of sonrotoclax was generally well-tolerated, and emergent toxicities were manageable in patients with mantle cell lymphoma.